%0 Journal Article
%T Efficacy of a Combination of Tanacetum parthenium, 5-Hydroxy Tryptophan and Magnesium (Aurastop) in the Prevention of High Frequency Migraine with Aura
%A Giorgio Dalla Volta
%A Paola Zavarise
%A Laura Perego
%A Alessandro Pezzini
%J Open Access Library Journal
%V 5
%N 10
%P 1-8
%@ 2333-9721
%D 2018
%I Open Access Library
%R 10.4236/oalib.1104939
%X
Object: To
verify the efficacy and safety of the new combination of Tanacetum parthenium 150 mg, 5-hydrossitriptophan (5-HTTP) 20 mg
and magnesium 185 mg (Aurastop) in the prophylactic treatment of high frequency migraine
with aura (MWA). According to the international headache classification (IHCD
3 beta
version) the aura phenomena have a duration of 5 - 60 minutes for any of the
usual disturbances (visual, somatosensory and speech disturbance) but no
classification describes the frequency of this phenomena. Patients who
experience migraine aura emphasize the emotional impact of such a phenomenon,
mostly because of the severe, though transient, disability caused by the aura
symptoms (i.e., inability to work or
driving a vehicle). Furthermore, a profound asthenia lasts for about 48 hours
after the resolution of the painful phase. Materials and Method: 18 patients
(F: n = 10, M: n = 8, mean age: 28) presenting with an ICHD-3 beta diagnosis of
migraine with aura (MWA) with a frequency of more than 5 attacks of migraine
with aura per month since at least 6 months, were enrolled in the survey and
treated with Aurastop© twice a day for a period of 3 months. Diary
cards were filled in during a 3-month period before the beginning of the
survey and during the 3-month duration of the study. The reduction of MWA
attacks per month was assessed as the primary end-point; the reduction of the
duration and disability of the aura and of the intensity of the headache were
considered as secondary end-points. Results: A statistically significant
reduction of MWA attacks/month was observed: more than 95% of the patients
referred a reduction >50% of the frequency, 66.6% a reduction of more than
70%, and 16.6% a complete disappearance of the attacks after the first week of
therapy.
Moreover, a sensible reduction of the duration and disability of the aura
phenomena was reported by more than 90% of the patients and, in the 55% of the
patients also a reduction of the intensity of the headache. No side effects
were reported. The efficacy started to appear during the first month of intake
and was maintained during the three months of therapy.
%K Migraine Aura
%K Migraine Therapy
%K Case-Only Study
%U http://www.oalib.com/paper/5300193